Collectively, these findings indicated that biNV-IL-15 could produce CD3+CD8+ CTLs in an antigen-specific manner in vivo via the spatiotemporally synchronous provision of IL-15 and tumor antigen to CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.